Background: There is limited research comparing both performance and brain control of walking between older adults with progressive and relapsing-remitting MS.
Objective: This study compared older adults with progressive and relapsing-remitting MS for differences in prefrontal cortex (PFC) activation in single- and dual-task-walking and practice-related effects on neural efficiency, walking, and cognitive performances.
Methods: Older adults with progressive (n = 32, age=65±6ys) and relapsing-remitting (n = 63, age=65±4ys) MS completed three conditions (single-task walk, single-task-alpha, i.e., cognitive interference task, and dual-task-walk) with three repeated trials wherein we measured PFC oxygenated hemoglobin (HbO), stride velocity and letter generation rate. Task, trial, and group effects and interactions were analyzed using linear mixed effects models.
Results: The task-related (i.e. single-to-dual task walking) increase in PFC HbO was greater in progressive than in relapsing-remitting MS (p < 0.001), while the practice-related decrease in dual-task PFC HbO was smaller in progressive than in relapsing-remitting MS (p < 0.001). Progressive MS was associated with slower stride velocity overall, but repeated trials resulted in faster stride velocity and correct letter generation rate for both groups.
Conclusions: Practice-related improvements in cognitive and motor performances coupled with reduced PFC HbO over dual-task walking trials suggest attenuated improvements of efficiency in brain control of attention-demanding locomotion in progressive MS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2024.106224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Int J MS Care
January 2025
Novartis Pharmaceuticals UK Ltd, London, United Kingdom.
Background: The PANORAMA survey aimed to assess current treatment practice for individuals with new diagnoses of relapsing-remitting multiple sclerosis (RRMS) in the United Kingdom and to explore variations in treatment approaches with an emphasis on escalation vs early high-efficacy treatment (HET) and treatment goals.
Methods: Health care professionals (HCPs) from the UK treating patients with RRMS took part in interviews facilitated by a structured questionnaire. Data were analyzed descriptively using quantitative or qualitative methods, as appropriate.
Disseminated enterovirus infection treated with intravenous immunoglobulin in a patient on maintenance ocrelizumab for multiple sclerosis.
BMJ Case Rep
January 2025
Infectious Diseases, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
We present a case of a woman in her 40s with disseminated enterovirus infection in the setting of maintenance therapy with ocrelizumab for relapsing-remitting multiple sclerosis. The patient originally presented with fever, bilateral lower limb swelling and hypoalbuminaemia. She subsequently developed a productive cough and diarrhoea, and a viral respiratory multiplex panel detected rhino/enterovirus.
View Article and Find Full Text PDFNeuro-Behçet's disease: an update of clinical diagnosis, biomarkers and immunopathogenesis.
Clin Exp Immunol
January 2025
Department of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Neuro-Behçet's disease (NBD) is a more severe but rare symptom of Behçet's disease (BD), which is mainly divided into parenchymal NBD (p-NBD) involving brain stem, spinal cord, and cerebral cortex. Non-p-NBD manifests as intracranial aneurysm, cerebral venous thrombosis, peripheral nervous system injuries, and mixed parenchymal and non-parenchymal disease. P-NBD is pathologically characterized by perivasculitis presenting with cerebrospinal fluid (CSF) pleocytosis, elevated total protein, and central nervous system (CNS) infiltration of macrophages and neutrophils, which are subdivided into acute and chronic progressive stages according to relapsing-remitting courses and responses to steroids.
View Article and Find Full Text PDFMucosal Bacterial Immunotherapy Attenuates the Development of Experimental Colitis by Reducing Inflammation Through the Regulation of Myeloid Cells.
Int J Mol Sci
December 2024
Department of Cell Biology, Faculty of Medicine, UCM, 28040 Madrid, Spain.
Ulcerative colitis is a chronic relapsing-remitting and potentially progressive form of inflammatory bowel disease in which there is extensive inflammation and mucosal damage in the colon and rectum as a result of an abnormal immune response. MV130 is a mucosal-trained immunity-based vaccine used to prevent respiratory tract infections in various clinical settings. Additionally, MV130 may induce innate immune cells that acquire anti-inflammatory properties and promote tolerance, which could have important implications for chronic inflammatory diseases such as ulcerative colitis.
View Article and Find Full Text PDFRelationship Between T-helper 1 Inflammatory Biomarkers and Hematological Index Responses in Patients With Multiple Sclerosis.
Cureus
December 2024
Basic Sciences, Hawler Medical University, Erbil, IRQ.
Background Multiple sclerosis is a chronic, progressive, disabling disease associated with a high rate of infection, evidence of chronic inflammation, and a high mortality rate. Abnormalities of serum cytokines and changes in the activity of inflammatory cells were associated with relapsing-remitting multiple sclerosis (MS-RR). This study aims to introduce new inflammatory ratios derived from hematological and lipid indices as discriminators of T-helper (Th)-1/Th-2 activity in RR-MS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!